Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Covington
AstraZeneca
Mallinckrodt
Chinese Patent Office
UBS
Johnson and Johnson
McKesson
Merck

Generated: November 16, 2018

DrugPatentWatch Database Preview

Cardinal Health 414 Company Profile

« Back to Dashboard

What is the competitive landscape for CARDINAL HEALTH 414, and what generic alternatives to CARDINAL HEALTH 414 drugs are available?

CARDINAL HEALTH 414 has six approved drugs.

There are two US patents protecting CARDINAL HEALTH 414 drugs.

Summary for Cardinal Health 414
US Patents:2
Tradenames:6
Ingredients:6
NDAs:6

Drugs and US Patents for Cardinal Health 414

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cardinal Health 414 FLUDEOXYGLUCOSE F18 fludeoxyglucose f-18 INJECTABLE;INTRAVENOUS 203603-001 Nov 13, 2015 AP RX No No ➤ Sign Up ➤ Sign Up
Cardinal Health 414 LYMPHOSEEK KIT technetium tc-99m tilmanocept INJECTABLE;INJECTION 202207-001 Mar 13, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up
Cardinal Health 414 AMMONIA N 13 ammonia n-13 INJECTABLE;INTRAVENOUS 203700-001 Feb 25, 2013 AP RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Cardinal Health 414 Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB07/011 United Kingdom ➤ Sign Up PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
C/GB06/021 United Kingdom ➤ Sign Up PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201
C/GB98/040 United Kingdom ➤ Sign Up PRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
QuintilesIMS
US Department of Justice
Covington
Accenture
US Army
Fuji
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.